DA Davidson Forecasts Strong Price Appreciation for USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences (NYSE:USNA) had its price target hoisted by equities researchers at DA Davidson from $35.00 to $38.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. DA Davidson’s target price suggests a potential upside of 5.06% from the company’s previous close.

Separately, StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 28th.

USANA Health Sciences Stock Performance

Shares of USNA opened at $36.17 on Thursday. The stock has a 50 day simple moving average of $37.86 and a 200 day simple moving average of $39.59. USANA Health Sciences has a 52-week low of $31.44 and a 52-week high of $52.75. The firm has a market capitalization of $689.40 million, a PE ratio of 12.78, a P/E/G ratio of 1.25 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. During the same period in the prior year, the business earned $0.59 EPS. Equities research analysts predict that USANA Health Sciences will post 2.45 EPS for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC raised its position in USANA Health Sciences by 4.4% in the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock valued at $292,000 after purchasing an additional 322 shares during the last quarter. Martingale Asset Management L P increased its stake in shares of USANA Health Sciences by 2.1% in the third quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock valued at $634,000 after buying an additional 340 shares during the period. KBC Group NV raised its holdings in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. Safe Harbor Fiduciary LLC acquired a new stake in USANA Health Sciences during the 3rd quarter worth approximately $30,000. Finally, Public Sector Pension Investment Board grew its holdings in USANA Health Sciences by 5.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 24,270 shares of the company’s stock worth $1,098,000 after acquiring an additional 1,242 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.